ACM
HRMY icon

Altium Capital Management’s Harmony Biosciences HRMY Stock Holding History

Altium Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-117,000
Closed -$3.83M – 77
2023
Q3 		$3.83M Sell
117,000
-32,889
-22% -$1.14M 2% 19
2023
Q2 		$5.27M Buy
149,889
+119,889
+400% +$4.14M 3.99% 8
2023
Q1 		$980K Buy
+30,000
New +$1.37M 0.54% 48
2022
Q3 		– Sell
-50,000
Closed -$2.44M – 144
2022
Q2 		$2.44M Buy
+50,000
New +$2.25M 0.98% 40

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Altium Capital Management's HRMY Position: Q4 2023 in Review

Altium Capital Management sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 117,000 shares — an estimated $3.83M sold.

Altium Capital Management first reported a position in HRMY in Q2 2022 and held it in 4 quarters. The position peaked at $5.27M in Q2 2023. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

  • Altium Capital Management reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
  • Altium Capital Management sold 117,000 Harmony Biosciences shares in Q4 2023, an estimated $3.83M.
  • Altium Capital Management first reported a position in Harmony Biosciences in Q2 2022 and held it in 4 quarters.
  • Altium Capital Management's Harmony Biosciences position peaked at $5.27M in Q2 2023.
  • 221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on Altium Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.